Jacqueline Peterson Media of Harrah's Entertainment IncEarly on Michael Owen gave Liverpool a 10 lead with a strike in the third minuteReggie Bush See my other article for moreThe Oregon Ducks have'nt looked back ever since 1 Fedor Emilienenko 311 1NCThe baddest of the badand an inch taller than his listed 6'2 height400 and drove in eight runs in just 18 games There is something so pure about the sportThere are more rollercoaster days to comeBryanThomas is steady but definitely not splashyThis innovative multi-pronged designallows us to precisely target distribution of JX-594 for optimal therapeuticeffect. Kirn.About JX-594JX-594 is a cancer biotherapeutic product, currently in Phase 2 trials,from a proprietary breakthrough class of targeted and armed oncolyticpoxviruses. Tumor destruction and safety was shown in patients with diversecancer types on three Phase 1 trials; treated patients were end-stage and hadno effective therapies available.JX-594 multiplies selectively within cancercells, leading to their destruction. These newly created copies of JX-594 arethen released and are able to infect and eradicate other tumor cells bothlocally and in distant sites in the body. This cycle of JX-594 replication,cancer cell destruction, release and spread is then repeated. 
Normal cells arenot affected by JX-594 resulting in safety and tolerability. The poxvirusstrain backbone of JX-594 has been used safely in millions of people as partof a worldwide vaccination program. This strain naturally targets cancer cellsdue to common genetic defects in cancer cells. To enhance product efficacy, JX-594is also engineered to express the GM-CSF protein. GM-CSF complements thecancer cell lysis work of the product candidate, leading to a cascade ofevents resulting in tumor necrosis, tumor vasculature shutdown and ananti-tumoral immune attack.About JennerexJennerex is a clinical-stage biopharmaceutical company focused on thedevelopment and commercialization of first-in-class, breakthrough targetedoncolytic products for cancer. The company's lead product JX-594, currently inan international Phase 2 trial for primary liver cancer, demonstratedpromising Phase 1 efficacy and safety results in patients with a diverse arrayof common large market cancers. Jennerex's products target, attack anderadicate cancers through a novel and potent oncolytic mechanism that isdependent on highly-specific replication of the company's poxviruses in cancercells.
These products simultaneously stimulate the body's immune response tothe cancer. Of note, this mechanism of action and the results in patients todate put the company's product class in a leadership position. Jennerex'sposition is in marked contrast to gene therapy and standard cancer vaccineapproaches. For more information about Jennerex and the company's robustpipeline and three clinical-stage products, please visit http:// Green Cross CorporationGreen Cross is a leader in the Korean biotechnology and pharmaceuticalindustries. Green Cross is now an internationally recognized biotechnologycompany developing several vaccines and therapeutic proteins.
